Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 12 art units • 13 examiners • 0 of 14 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days
Daiichi Sankyo Company, Limited has 15 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 13 distinct examiners and 12 distinct art units. GALSTER, SAMUEL LEONARD is the busiest examiner, with 2 pending matters, so the record reflects broad examiner and art-unit distribution with limited concentration in the busiest assignment.
This distribution calls for formal portfolio coordination, including consistent claim terminology, disclosure support, and tracking of examiner-specific issues. The difference between the number of pending actions and distinct examiners indicates that some examiner relationships cover more than one matter, while the art-unit count shows additional grouping at the technology-routing level. Counsel should use common technical positions where appropriate but preserve application-specific response records.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (36%) |
| §112 only | 2 (14%) |
| Double-patenting + other | 4 (29%) |
| Multi-statute (no §101) | 3 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 2 | 52.1% | +42.2% |
| LIU, TRACY | 1 | 54.5% | +26.9% |
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
| ANTHOPOLOS, PETER | 1 | 57.4% | +58.6% |
| TATGE, LEXUS MARC | 1 | 25.0% | +100.0% |
| PETRASH, HILARY ANN | 1 | 65.6% | +50.2% |
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
| LU, CHENG | 1 | 53.8% | +64.6% |
| PAK, YONG D | 1 | 74.7% | +14.2% |
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016864 | COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE WITH HER DIMERIZATION INHIBITOR | SKOKO III, JOHN JOSEPH | 71d overdue |
| 18265756 | STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED | TATGE, LEXUS MARC | 36d overdue |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | GALSTER, SAMUEL LEONARD | 6d |
| 18562059 | HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE | ANTHOPOLOS, PETER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016864 | COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE WITH HER DIMERIZATION INHIBITOR | SKOKO III, JOHN JOSEPH | 71d overdue |
| 18265756 | STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED | TATGE, LEXUS MARC | 36d overdue |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | GALSTER, SAMUEL LEONARD | 6d |
| 18025896 | A Scoring Method for an Anti-HER2 Antibody-Drug Conjugate Therapy | LU, CHENG | 21d |
| 18252838 | COMPLEX OF BETA-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE | GALSTER, SAMUEL LEONARD | 22d |
| 18249421 | METHOD OF PRODUCING 3-METHYL-4-HALO-INDOLE DERIVATIVE | ISMAIL, REHANA | 35d |
| 18708875 | PHARMACEUTICAL COMPOSITION HAVING EXCELLENT DISSOLUTION PROPERTIES | LIU, TRACY | 62d |
| 18561868 | INFLUENZA VIRUS NUCLEIC ACID LIPID PARTICLE VACCINE | GILL, RACHEL B | — |
| Art Unit | Apps |
|---|---|
| 1693 | 2 |
| 1643 | 2 |
| 1614 | 1 |
| 1671 | 1 |
| 1611 | 1 |
| 1637 | 1 |
| 1644 | 1 |
| 1625 | 1 |
| 1642 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18708875 | PHARMACEUTICAL COMPOSITION HAVING EXCELLENT DISSOLUTION PROPERTIES | LIU, TRACY | 1614 | §103 | Non-Final OA | 62d | Pending | May 09, 2024 |
| 18561868 | INFLUENZA VIRUS NUCLEIC ACID LIPID PARTICLE VACCINE | GILL, RACHEL B | 1671 | §103 | Final Rejection | — | Pending | Nov 17, 2023 |
| 18562059 | HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE | ANTHOPOLOS, PETER | 1611 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | GALSTER, SAMUEL LEONARD | 1693 | §103§112 | Non-Final OA | 6d | Pending | Jul 26, 2023 |
| 18265756 | STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED | TATGE, LEXUS MARC | 1637 | §103§112DP | Non-Final OA | 36d overdue | Pending | Jun 07, 2023 |
| 18252838 | COMPLEX OF BETA-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE | GALSTER, SAMUEL LEONARD | 1693 | §103 | Final Rejection | 22d | Pending | May 12, 2023 |
| 18036289 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY | PETRASH, HILARY ANN | 1644 | §102§103§112DP | Non-Final OA | — | Pending | May 10, 2023 |
| 18249421 | METHOD OF PRODUCING 3-METHYL-4-HALO-INDOLE DERIVATIVE | ISMAIL, REHANA | 1625 | §112 | Final Rejection | 35d | Pending | Apr 18, 2023 |
| 18025896 | A Scoring Method for an Anti-HER2 Antibody-Drug Conjugate Therapy | LU, CHENG | 1642 | §112 | Non-Final OA | 21d | Pending | Mar 11, 2023 |
| 18024258 | NOVEL ENDO-ß-N-ACETYLGLUCOSAMINIDASE | PAK, YONG D | 1652 | §103 | Non-Final OA | — | Pending | Mar 01, 2023 |
| 18016864 | COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE WITH HER DIMERIZATION INHIBITOR | SKOKO III, JOHN JOSEPH | 1643 | §102§103§112 | Final Rejection | 71d overdue | Pending | Jan 18, 2023 |
| 17625328 | METHOD FOR PRODUCING INSULIN-PRODUCING CELL USING DIHYDROINDOLIZINONE DERIVATIVES | BATES, KEENAN ALEXANDER | 1631 | §112DP | Final Rejection | — | Pending | Jan 06, 2022 |
| 17262590 | EFFECTIVE METHOD FOR MANUFACTURING ANTIBODY-DRUG CONJUGATE | VAN DRUFF, SYDNEY | 1643 | §103 | Final Rejection | 2d overdue | Pending | Jan 22, 2021 |
| 16640914 | ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME | KIM, YUNSOO | 1641 | §103DP | Final Rejection | 81d overdue | Pending | Feb 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDaiichi Sankyo Company, Limited has 14 pending office actions as of October 2026, spread across 12 art units and 13 examiners.
Samuel Leonard Galster has the most, with 2 of Daiichi Sankyo Company, Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
